Fuse Science announces rollout strategy for its energy drops — select Walgreens near PGA tourneys
MIAMI LAKES, Fla. — Fuse Science on Thursday announced extended distribution for its PowerFuse and ElectroFuse energy drops across select Walgreens stores in the Ponte Verde, Fla., market for the Players Championship Tournament. Point-of-purchase displays feature NFL’s Arian Foster and David Ortiz of MLB’s Boston Red Sox.
The Fuse Science distribution strategy is focused on rolling out product lines within Walgreens locations situated near select PGA tournaments around the country up until, and including, the 2013 U.S. Open in June.
"We are very pleased with the new distribution relationship we have established with Walgreens," stated Brian Tuffin, CEO of Fuse Science. "We’ve been working extremely hard in establishing the right alliances with strong financial terms to ensure the success of the consumer business. We have been very deliberate in our strategy, and continue to make measured progress against our primary objective to build a major national distribution presence for the ‘Powered By Fuse’ brands," he said. "This distribution agreement, and others we expect to announce in the future, reflects a milestone for the retail distribution of our products that we believe will set the stage for the ramp-up of revenue generation and substantial growth of Fuse Science."
FDA approves Breo Ellipta for COPD
SILVER SPRING, Md. — The Food and Drug Administration has approved a new treatment for chronic obstructive pulmonary disease, the agency said Friday.
The FDA announced the approval of Breo Ellipta (fluticasone furoate and vilanterol), a once-per-day inhaler made by GlaxoSmithKline and Theravance for long-term treatment of COPD, which includes chronic bronchitis and emphysema.
"COPD is a serious disease that makes breathing difficult," FDA Office of Drug Evaluation II director Curtis Rosebraugh said. "The availability of new, long-term maintenance medications provides additional treatment options for the millions of Americans who suffer with COPD."
FDA approves Novartis’ Ilaris for rare childhood arthritis
EAST HANOVER, N.J. — The Food and Drug Administration has approved a biotech drug made by Novartis for treating a form of arthritis that affects children, the Swiss drug maker said Friday.
Novartis announced the approval of Ilaris (canakinumab) for active systemic juvenile idiopathic arthritis in patients ages 2 years and older. The company said the drug was the first once-per-month drug for injection under the skin to be approved for SJIA. The disease is a rare and disabling form of arthritis characterized by spiking fever, rash and arthritis that can affect children as young as 2 years and continue into adulthood, according to studies. The drug is also approved for treating rare, lifelong and debilitating genetic disorders known as cryopyrin-associated periodic syndromes.
"In the United States, this approval marks the second Ilaris indication for patients living with rare, autoinflammatory conditions," Novartis Pharmaceuticals global head of development Timothy Wright said.